Predictive factors of age-related macular degeneration evolution in response to anti-vascular endothelial growth factor therapy
Keywords:
AMD, macular degeneration, AMD evolution, AMD treatment, anti-VEGFAbstract
Age-related macular degeneration (AMD) is an acquired pathology of the retina that causes loss of central vision. There are specific therapeutic methods that are used at different stages of the pathology. Exudative form is treated with inhibitors of the vascular endothelial growth factor (anti-VEGF) used in different therapeutic schemes. This work will be focused more on the effect of bevacizumab. The effect of treatment is determined by different factors like age, gender, genetics, environment, and clinical factors. The complexity of the clinical factors is of particular interest because they can help us to predict the evolution of the pathology from the beginning of the treatment. The aim of this work is to study the predictors of AMD in order to understand the variability of response to anti-VEGF and to develop a mechanism for determining the patients who will not respond to anti-VEGF. This article comes with useful information about the effects of anti-VEGF in different clinical situations intending to bring a real benefit in the practical activity. In this review article were analyzed the scientific portals like PubMed and Google Scholar. Following the study of relevant sources it has been concluded that age, sex, genetics and clinical factors influence to direct the evolution of AMD under anti-VEGF treatment. The analysis of the factors involved in the variability of the pathological process response to anti-VEGF treatment allows the development of an algorithm for the stratification of patients with AMD.
References
1. Lorés-Motta L., Riaz M., Grunin M. et al. Association of genetic variants with response to anti-vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol. 2018;136(8):875-884. https://doi.org/10.1001/jamaophthalmol.2018.2019
2. Boyer D.S., Antoszyk A.N., Awh C.C., Bhisitkul R.B., Shapiro H., Acharya N.R.; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.Ophthalmology. 2007;114(2):246-252. https://doi.org/10.1016/j.ophtha.2006.10.045
3. Kaiser P.K., Brown D.M., Zhang K. et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850-857. https://doi.org/10.1016/j.ajo.2007.08.012
4. van Asten F., Rovers M.M., Lechanteur Y.T. et al. Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2014;21(6):347-355. https://doi.org/10.3109/09286586.2014.949010
5. Yang S., Zhao J., Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857-1867. https://doi.org/10.2147/DDDT.S97653
6. Finger R.P., Wickremasinghe S.S., Baird P.N., Guymer R.H. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2014 https://doi.org/10.1016/j.survophthal.2013.03.009 Ophthalmic Res. 2017;58(1):49-55.
7. Holz F.G., Amoaku W., Donate J., Guymer R.H., Kellner U., Schlingemann R.O..et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663-71. https://doi.org/10.1016/j.ophtha.2010.12.019
8. Smith W., Mitchell P., Wang J.J. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997 May;25 Suppl 1:S13-5. Disponibil pe: PMID: 9267614. https://doi.org/10.1111/j.1442-9071.1997.tb01745.x
9. CATT Research Group, Martin D.F., Maguire M.G., Fine S.L., Ying G.S., Jaffe G.J., Grunwald J.E. Ranibizumab and bevacizumab for treatment of neovascular age-related Macular degeneration. Two-year results. Ophthalmology. 2012;119:1388-98. https://doi.org/10.1016/j.ophtha.2012.03.053
10. Frampton J.E. Ranibizumab: A review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013;30:331-58. https://doi.org/10.1007/s40266-013-0077-9
11. Arnold J.J., Markey C.M., Kurstjens N.P. et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMCOphthalmol. 2016 Mar 24;16:31. https://doi.org/10.1186/s12886-016-0207-3
12. Grunwald J.E., Daniel E., Huang J., Ying G.S., Maquire M.G., Toth C.A. et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatment trials. Ophthalmology. 2014;121:150-61. https://doi.org/10.1016/j.ophtha.2013.08.015
13. Guymer R.H., Markey C.M., McAllister I.L. et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2019;126(5):723-734. https://doi.org/10.1016/j.ophtha.2018.11.025
14. Lalwani G.A., Rosenfeld P.J., Fung A.E., Dubovy S.R., Michels S., Feuer W. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular ager
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
